Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
Status
Conditions
Treatments
Details and patient eligibility
About
The primary purpose of this study is to demonstrate that a continuous infusion of intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic levels of heparin in high-risk critically ill medical patients as compared with guideline recommended subcutaneous heparin. Antifactor Xa assay, a laboratory test to measure the anticoagulant activity of heparin, or the ability of heparin to thin the blood, will be used to demonstrate that Intravenous administration is more effective.
Sex
Ages
Volunteers
Inclusion criteria
- Admission to the medical ICU (MICU)
- High-risk for Venous Thromboembolism (VTE) ≥ 1 of the following:
- Body Mass Index (BMI) ≥ 30 kg/m2
- Personal or family history of VTE
- Receiving vasopressors
Exclusion criteria
- Indication for therapeutic anticoagulation
- Evidence of deep vein thrombosis (DVT) on ultrasonography at admission
- Indwelling intrathecal, epidural, or other indwelling deep catheters
- Recent (< 3 months) International Society of Thrombosis and Haemostasis (ISTH) major bleeding13
- Recent (< 3 months) major trauma
- Recent (< 3 months) neurosurgery or orthopedic surgery Pregnancy
- Contraindication to heparin or heparin products
Trial design
Primary purpose
Allocation
Interventional model
Masking
0 participants in 2 patient groups
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal